HIGHLIGHTS
- who: Jun Ni from the Guangdong Medical University, China have published the research: Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial, in the Journal: (JOURNAL) of March/16,/2022
- what: Effect of IP in Asian patients and the promising efficacy of camrelizumab plus apatinib as second-line regimen for ES-SCLC, this non-randomized trial was conducted to explore the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in patients with untreated ES-SCLC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.